Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study

7Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Cancer antigen 125 (CA125) is clinically used to monitor response to therapy in ovarian cancer and has been proposed for use in detecting ovarian cancer. This population-based study examines how demographic characteristics, gynecologic/reproductive history, chronic non-malignant medical conditions, history of non-ovarian cancer, lifestyle practices, and biomarkers of inflammation correlate with serum CA125 in both premenopausal and postmenopausal women without ovarian cancer across the United States. Methods: Participants were identified from the National Health and Nutrition Examination Survey 2001–2002. Linear and logistic regression models were applied. Results: Higher CA125 levels were found to correlate with younger age, Non-Hispanic White race/ethnicity, and lower body mass index. In premenopausal women (N = 1157), current smoking was associated with lower CA125 (− 24.95%, p = 0.008), and history of non-ovarian cancer was associated with higher CA125 (40.64%, p = 0.045) by multivariable linear regression; both current smoking (odds ratio (OR) = 0.42, p = 0.043) and oral contraceptive pill (OCP) use of 5–10 years (OR = 0.31, p = 0.032) were less likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression. In postmenopausal women (N = 1116), coronary artery disease (CAD) history was associated with higher CA125 (28.27%, p = 0.047) by multivariable linear regression; history of CAD (OR = 5.00, p = 0.011), history of breastfeeding (OR = 2.46, p = 0.026), and increased CRP level (OR = 1.41, p = 0.042) were more likely to be associated with having CA125 level ≥ 35 U/ml by multivariable logistic regression. Conclusions: Results suggest CA125 is lower in premenopausal women who are current smokers and OCP users of moderately longer duration but higher in those with non-ovarian cancer. CA125 is higher in those postmenopausal women with CAD, history of breastfeeding and elevated CRP level. These associations can inform clinical interpretation of individual patients’ CA125 levels.

Author supplied keywords

References Powered by Scopus

Cancer statistics, 2020

16821Citations
N/AReaders
Get full text

A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer

2006Citations
N/AReaders
Get full text

Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial

1126Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Molecular Management of High-Grade Serous Ovarian Carcinoma

11Citations
N/AReaders
Get full text

The Potential of MicroRNAs as Clinical Biomarkers to Aid Ovarian Cancer Diagnosis and Treatment

9Citations
N/AReaders
Get full text

Metabolic syndrome and risk of ovarian cancer: a systematic review and meta-analysis

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hu, X., Zhang, J., & Cao, Y. (2022). Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study. BMC Cancer, 22(1). https://doi.org/10.1186/s12885-022-09637-7

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

75%

Researcher 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

50%

Pharmacology, Toxicology and Pharmaceut... 1

17%

Sports and Recreations 1

17%

Biochemistry, Genetics and Molecular Bi... 1

17%

Save time finding and organizing research with Mendeley

Sign up for free